Talk Bio

Sentynl Therapeutics Receives FDA Approval for ZYCUBO, First US Treatment for Rare Menkes Disease

Fortress Biotech and Sentynl Therapeutics Fail to Secure FDA Approval for CUTX-101 in Rare Pediatric Menkes Disease

FDA Rejects CUTX-101 for Rare Copper Deficiency Due to Manufacturing Issues